Analyst Price Targets — XCUR
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| January 26, 2022 12:00 am | Keay Nakae | Chardan Capital | $12.00 | $4.94 | Pulse 2.0 | Exicure Stock (XCUR) Price Surges Today: Details You Should Know |
Latest News for XCUR
Phase 2 data demonstrate differentiated CXCR4 inhibition kinetics enabling same-day cell collection, with rapid lymphocyte mobilization supporting potential therapeutic applications beyond transplant Phase 2 data demonstrate differentiated CXCR4 inhibition kinetics enabling same-day cell collection, with rapid lymphocyte mobilization supporting potential therapeutic applications beyond transplant
REDWOOD CITY, Calif., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today announced that it will present a poster at the upcoming 2026 Tandem Meetings | Transplantation & Cellular Therapy Meetings of the American Society for Transplantation and Cellular Therapy (ASTCT) and Center for International Blood and…
Exicure, Inc. (NASDAQ: XCUR - Get Free Report) was the recipient of a significant decline in short interest in the month of December. As of December 31st, there was short interest totaling 139,368 shares, a decline of 42.7% from the December 15th total of 243,112 shares. Currently, 4.6% of the shares of the stock are sold
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for XCUR.
U.S. House Trading
No House trades found for XCUR.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.